Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that a Meeting of the Board of Directors of the Company will be held on Thursday, November 9, 2023, to consider and approve the following: Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023 and payment of Interim Dividend, if any, for the financial year 2023-24. Further to its letter dated September 27, 2023, informing about the closure of Trading Window of the Company from October 1, 2023, until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, the company has informed that the Trading Window will remain closed up to November 11, 2023, and shall be re-opened on November 12, 2023.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1816.25 |
Dr. Reddys Lab | 1345.00 |
Cipla | 1477.45 |
Lupin | 2163.25 |
Zydus Lifesciences | 973.90 |
View more.. |